'For
the quarter ending March 2024, consolidated net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 18.08% to Rs 929.8 crore compared to quarter ended March 2023. Operating profit margin has jumped from 21.56% to 27.67%, leading to 51.56% rise in operating profit to Rs 257.26 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.17% to 20.00%. Purchase of finished goods cost rose from 24.88% to 25.00%. Employee cost decreased from 20.83% to 16.89%. Other expenses fell from 17.36% to 12.96%. Other income rose 7.85% to Rs 29.83 crore. PBIDT rose 45.44% to Rs 287.09 crore. Provision for interest rose 18.46% to Rs 0.77 crore. Loan funds rose to Rs 18.67 crore as of 31 March 2024 from Rs 15.54 crore as of 31 March 2023. Inventories rose to Rs 525.05 crore as of 31 March 2024 from Rs 459.9...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Revenue up by 3.3% YoY to Rs 4304.7 crore in Q3FY2025
-
-
|